AstraZeneca to cap US out-of-pocket costs for inhalers at $35 per month By Reuters
AstraZeneca to cap US out-of-pocket costs for inhalers at $35 per month…
61,500€
0,82%
Echtzeit-Aktienkurs Astrazeneca PLC (Spons. ADRs)
Bid:
Ask:
Nachrichten zur Astrazeneca PLC (Spons. ADRs) Aktie
Kommunen fordern "Atempause" bei Flüchtlingen - TE-Wecker am 18. März 2024
Kommunen fordern "Atempause" bei Flüchtlingen ++ EU schließt 7,4-Milliarden-Flüchtingsdeal mit Ägypten ++ Teilurteil in Corona-Prozess gegen AstraZeneca erwartet ++ neue…
Pharma Stock Roundup: AZNs New Acquisition, FDA Updates for NVO & LLY and More
AstraZeneca (AZN) is set to buy a private rare disease drugmaker. FDA delays decision on Lillys (LLY) donanemab and approves…
AstraZeneca: Milliardenschwerer Deal verkündet - Aktienanalyse
Kulmbach (www.aktiencheck.de) - AstraZeneca-Aktienanalyse von "Der Aktionär":
Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die Aktie des…
Biotech Rally Gets $100 Billion M&A Lift With More Deals to Come
A rash of dealmaking helped reverse the declining fortunes of biotech stocks over the last five months. And as AstraZeneca…
AstraZeneca: Rating gesenkt
Frankfurt (www.aktiencheck.de) - Rating-Update:
Die Analysten von ODDO BHF stufen die Aktie von AstraZeneca plc (ISIN: GB0009895292, WKN: 886455, Ticker-Symbol: ZEG,…
Amolyt Pharma Enters into Definitive Agreement to be Acquired by AstraZeneca
AstraZeneca will acquire Amolyt Pharma for up to $1.05 billion in total consideration…
AstraZeneca to buy Amolyt Pharma for $1.05 billion to boost rare diseases portfolio By Reuters
AstraZeneca to buy Amolyt Pharma for $1.05 billion to boost rare diseases portfolio…
AstraZeneca to acquire Amolyt
14 March, 2024
AstraZeneca to acquire Amolyt Pharma,
expanding late-stage rare disease pipeline
Amolyt development portfolio includes Phase III asset with potential to address…
AstraZeneca (AZN) to Acquire Amolyt Pharma for $1.05 Billion
AstraZeneca (AZN) enters into an agreement to acquire Amolyt Pharma to strengthen its rare disease pipeline by adding the latters…